Revivicor focuses on producing genetically modified pig organs for transplantation into humans.

Origins and Evolution

Founded in 2003 in Blacksburg, Virginia, Revivicor originated from PPL Therapeutics, the British company involved in the creation of Dolly the sheep, the first mammal cloned from an adult cell.

Innovations in Xenotransplantation

Revivicor has developed genetically modified pigs to produce organs compatible with the human body, reducing the risk of immune rejection. These pigs have specific genes deactivated and human genes inserted to facilitate the acceptance of their organs in human patients.

Notable Procedures

In January 2022, a team of American surgeons successfully transplanted a pig heart provided by Revivicor into David Bennett, a 57-year-old man with terminal heart failure.

Preparation of the Animals

Revivicor’s pigs are raised in controlled facilities, where they undergo genetic modifications to deactivate genes that could trigger rejection in humans. Additionally, human genes are inserted to increase the compatibility of the organs.

Impact and Future

Revivicor's advances in xenotransplantation offer hope for addressing the shortage of organs available for transplantation, providing a viable alternative for patients on waiting lists.

As the company continues to refine its techniques and obtain regulatory approvals, genetically modified pig organs are expected to become an effective solution for saving human lives.